MRA (magnetic resonance angiography) is a specialized MRI technique for imaging blood vessels. It isn’t simply MRI with contrast: some MRA studies use gadolinium contrast (contrast-enhanced MRA) to improve vessel detail, while others use non-contrast methods (time-of-flight, phase-contrast). Choice depends on the clinical question, anatomy, and kidney function, since gadolinium is avoided in severe renal impairment.

MRA with intravenous contrast is generally not painful. The MRI itself is painless, though lying still and confined can be uncomfortable or provoke claustrophobia. The contrast injection may cause brief stinging at the IV site or a warm metallic taste and flushing; most effects are mild and short-lived. Serious reactions are rare—tell staff about allergies or kidney problems beforehand.

An MRA (magnetic resonance angiography) of the brain typically costs: in the US, roughly $400–$3,500 (higher with contrast or at hospitals); in the UK it’s free on the NHS or about £200–£800 privately; in India about ₹2,500–₹15,000. Final price depends on contrast use, facility type, and insurance coverage; confirm with your provider for an exact quote.

Brain MRI (magnetic resonance imaging) uses magnetic fields and radio waves to produce detailed images of brain anatomy, helping detect tumors, stroke, inflammation, infection, and structural abnormalities. MRA (magnetic resonance angiography) is a specialized MRI that visualizes cerebral blood vessels to assess aneurysms, stenosis, or occlusion. Both are noninvasive, use no ionizing radiation, and may use gadolinium contrast when needed.

MRA (magnetic resonance angiography) images cerebral blood vessels. It may show indirect tumor signs, such as displaced vessels or abnormal vascularity, but it is not reliable for detecting or characterizing most brain tumors. For suspected brain tumors, a dedicated contrast-enhanced brain MRI (and sometimes CT, MR spectroscopy or biopsy) is required for accurate diagnosis and treatment planning.

Mineralocorticoid receptor antagonists (MRAs) raise risks of hyperkalaemia and worsening kidney function, especially with ACE inhibitors/ARBs or potassium supplements. They can cause low blood pressure, dizziness, dehydration, and — with spironolactone — hormonal effects (breast swelling, gynecomastia, menstrual changes, sexual dysfunction). Rare allergic reactions and drug interactions can occur, so regular blood tests (potassium, creatinine) and monitoring are essential.